- Home
- LBTYB vs SRRK Comparison
LBTYB vs SRRK Comparison
Compare LBTYB & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYB | SRRK |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | Bermuda | United States |
| Employees | 6636 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.9B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | LBTYB | SRRK |
|---|---|---|
| Price | $12.80 | $44.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $55.10 |
| AVG Volume (30 Days) | 11.7K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.41 | N/A |
| Revenue Next Year | $2.10 | $449.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.20 | $22.71 |
| 52 Week High | $29.01 | $49.82 |
Technical Indicators
Market Signals| Indicator | LBTYB | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 46.58 |
| Support Level | $10.28 | $41.54 |
| Resistance Level | $13.04 | $48.31 |
| Average True Range (ATR) | 0.63 | 2.28 |
| MACD | -0.15 | -0.24 |
| Stochastic Oscillator | 14.72 | 39.93 |
Price Performance
Historical ComparisonAbout LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.